Enhancing plasmacytoid dendritic cell functionality with all-trans retinoic acid for improved multiple myeloma therapy

This is the authors' abstract. We don't add key points for this paper.

, RA combined with CpG or Resiquimod significantly improves the survival of MM-bearing mice, with even greater pro-survival benefits observed when RA, Resiquimod, and bortezomib are combined. These findings demonstrate that RA rejuvenates pDCs, leading to improved control of MM growth in preclinical models, offering novel insights into developing more effective MM therapies.